Journal info
|
||
Select Journal
Journals
Bratislava Medical Journal Endocrine Regulations General Physiology and Biophysics Neoplasma 2024 Ahead of print 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 Acta Virologica Studia Psychologica Cardiology Letters Psychológia a patopsych. dieťaťa Kovove Materialy-Metallic Materials Slovenská hudbaWebshop Cart
Your Cart is currently empty.
Info: Your browser does not accept cookies. To put products into your cart and purchase them you need to enable cookies.
Neoplasma Vol.69, No.1, p.95–102, 2022 |
||
Title: Identification of driver genes and target drugs-related genes in liver cancer based on targeted next generation sequencing | ||
Author: Yunlong Cui, Liwei Sun, Hailong Wang, Zhenzhen Zhang, Hongxia Dai, Pengfei Liu | ||
Abstract: The purpose of this study was to identify gene mutations, high frequency mutations, and driver genes in liver cancer, and the marketed approved drugs of these genes, to provide evidence for targeted treatment of liver cancer since it is one of the most common cancers worldwide. 34 patients with liver cancer were included, and their blood samples were collected. The pathway enrichment analysis of the mutation gene was carried out through the KEGG database, and the genes with marketed approved drugs were screened according to the Pharmalaxy database. A total of 6612 mutations in 1241 genes were identified in 34 patients, in which 22 genes mutated in at least 40% of the samples and were thought to be high frequency mutation genes. All the mutations were analyzed using the MutSigCV software, and 30 genes with q < 0.1 and P < 0.05 were selected out as driver genes. Among them, LRP1B, MYC, NF1, and KEAP1 were coincident with high frequency mutation genes, which were considered key driver genes. Afterward, 181 genes with P < 0.05 in MutSigCV software were analyzed for pathway enrichment. These genes were mainly enriched in four pathways, including MAPK mTOR, p53/cell cycle, and JAK-STAT pathways. Finally, there were 15 genes four pathways that had marketed approved target drugs. To conclude, LRP1B, MYC, NF1, and KEAP1 were the candidate key driver genes for liver cancer, which might provide new insights for targeted therapy of liver cancer. |
||
Keywords: liver cancer; gene mutation; driver gene; targeted therapy | ||
Published online: 27-Oct-2021 | ||
Year: 2022, Volume: 69, Issue: 1 | Page From: 95, Page To: 102 | |
doi:10.4149/neo_2021_210902N1258 |
||
|
download file |
|